3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
18
Gastrointestinal
12
Gynecologic
6
Tumor-Agnostic
4
Thoracic
3
Sarcoma
3
CNS
3
Head & Neck
2
Genitourinary
2
Dermatologic
1
Conditions
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Anus Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
29
Nivolumab
29
Specimen Handling
24
Ipilimumab
19
Magnetic Resonance Spectroscopy
17
Biopsy
11
CTLA-4 Antigen
9
Opdualag
8
Cyclophosphamide
8
relatlimab
6
Paclitaxel
6
trametinib
5
fludarabine
5
cemiplimab
5
Carboplatin
5
fludarabine phosphate
4
dabrafenib
4
binimetinib
4
avelumab
4
HhAntag691
4
lifileucel
3
capivasertib
3
atezolizumab
3
aldesleukin
3
X-Rays
3
Temozolomide
3
Taxes
3
Surgical Procedures, Operative
3
Standard of Care
3
Pemetrexed
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
trastuzumab deruxtecan
×
Dermatologic
×
30 days
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled